Teva Pharmaceutical Industries Ltd.

Director's Dealing • Mar 9, 2022

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

Instruction 1(b).

Form 5 obligations may continue. See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Schultz Kåre			2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Ltd. [TEVA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ 10% Owner X
(Last)	(First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,		3. Date of Earliest Transaction (Month/Day/Year) 03/04/2022	Director Officer (give title below)____ Other (specify below) X President and CEO
(Street) Tel Aviv L3 6944020 (City) (State) (Zip)			4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form:	7. Nature of Indirect Beneficial
		(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
(1) Ordinary Shares	03/04/2022		M		59,701	A	(2)	1,192,197	D
(1) Ordinary Shares	03/04/2022		M		162,593	A	(2)	1,354,790	D
(1) Ordinary Shares	03/05/2022		M		71,292	A	(2)	1,426,082	D

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned	10. Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)
Restricted Share Units	(2)	03/04/2022		M			59,701	(3)	(3)	Ordinary Shares (1)	59,701	\$ 0	59,702	D
Restricted Share Units	(2)	03/04/2022		M			162,593	(4)	(4)	Ordinary Shares (1)	162,593	\$ 0	0	D
Restricted Share Units	(2)	03/04/2022		A		402,144		(5)	(5)	Ordinary Shares (1)	402,144	\$ 0	402,144	D
Restricted Share Units	(2)	03/05/2022		M			71,292	(6)	(6)	Ordinary Shares (1)	71,292	\$ 0	213,879	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Explanation of Responses:

(1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

(2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

• (3) Restricted share units were granted on March 4, 2019, with 59,701 having vested on each of March 4, 2021 and March 4, 2022 and 59,702 vesting on March 4, 2023.
• (4) Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.
• (5) Restricted share units were granted on March 4, 2022, with 100,536 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.
• (6) Restricted share units were granted on March 5, 2021, with 71,292 having vested on March 5, 2022, 71,292 vesting on each of March 5, 2023 and March 5, 2024, and 71,295 vesting on March 5, 2025.

/s/ Dov Bergwerk as attorney-in-fact for Kare Schultz 03/08/2022

**Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.